RecruitingMajor Depressive Disorder (MDD)

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Eligible age

18–75 yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.

Sponsor: Draig Therapeutics Ltd

You may qualify if…

✓ The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent
✓ Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.
✓ Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).

You may not qualify if…

✕ Pregnant or breastfeeding or plans to become pregnant during the study.
✕ Unstable medical condition or unstable chronic disease.
✕ Significant neurological abnormality.
✕ History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening.
✕ History of seizure.
✕ In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.